Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.68 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123050 | 0.93 | PTPN1 (0.69) | PTPN1GPR132ITGB3ITGA2BGPR34 | |
| SCHEMBL1123437 | 0.91 | PTPN1 (0.67) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL1123011 | 0.89 | GPR132 (0.59) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL1123517 | 0.89 | PTPN1 (0.64) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL27658914 | 0.88 | GPR132 (0.77) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL1123033 | 0.88 | GPR132 (0.77) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL1123299 | 0.88 | GPR132 (0.77) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL1123232 | 0.88 | GPR132 (0.77) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL1122757 | 0.87 | GPR132 (0.78) | PTPN1GPR132ITGB3ITGA2BPPARG | |
| SCHEMBL27638089 | 0.87 | GPR132 (0.61) | PTPN1GPR132ITGB3ITGA2BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | PTPN1 2708/4885GPR132 122/4885ITGB3 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.